Continuous infusion of high-dose ulinastatin during surgery does not improve early postoperative clinical outcomes in patients undergoing radical lung cancer surgery: A pilot study

Leng Zhou¹, Haidan Lan¹, Qinghua Zhou², Xiao Jun Tang², Daxing Zhu², Jianming Yue¹ & Bin Liu¹

1 Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, China
2 The Lung Cancer Center, West China Hospital of Sichuan University, Chengdu, China

Keywords
Non-small cell lung cancer; postoperative pulmonary complications; thoracotomy; ulinastatin.

Correspondence
Bin Liu, Department of Anesthesiology, West China Hospital of Sichuan University, No. 37, Guoxuxiang, Chengdu 610041, China.
Tel: +86 189 8060 1540
Fax: +86 28 8542 3593
Email: zhoulenghx@foxmail.com; liubinhx@foxmail.com

¹Co-first author.

Received: 21 March 2016;
Accepted: 6 May 2016.

doi: 10.1111/1759-7714.12371

Thoracic Cancer 7 (2016) 581–587 © 2016 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Abstract
Background: Ulinastatin can prevent the perioperative increase in proinflammatory cytokines for lung resection surgery; however, its impact on early clinical outcomes remains unknown.

Methods: The study enrolled 108 non-small cell lung cancer (NSCLC) patients who were randomly allocated into two groups: ulinastatin (group U) and control (group C). Patients in group U (n = 52) were continuously intravenously infused with ulinastatin at a rate of 20 000 U/kg/hour for the first hour after anesthesia induction, and then at a rate of 5000 U/kg/hour until the conclusion of surgery. Patients in group C (n = 56) received an equivalent volume of normal saline. The primary outcome was to record the postoperative pulmonary complications that occurred during hospital stay. Other clinical courses, such as hospital mortality, blood loss, respiratory parameters, postoperative chest drainage, and duration of intensive care unit and postoperative hospital stay, were also observed and analyzed.

Results: There were no significant differences between the two groups in early postoperative pulmonary complications, hospital mortality, blood loss, or other perioperative laboratory values, except for the duration of postoperative chest drainage and serum creatinine level. The frequency of pulmonary complications was lower in patients treated with ulinastatin compared with the control (38.46% in group U vs. 48.21% in group C).

Conclusion: Administration of high-dose ulinastatin during surgery did not reduce postoperative pulmonary complications, hospital mortality, or hospital stay for patients undergoing lung radical thoracotomy. However, a protective trend of ulinastatin was observed.

Introduction
Lung cancer is one of the most common cancers and the leading cause of cancer related death worldwide.¹–³ Surgery remains the best curative option for patients with lung cancer.⁴ However, postoperative pulmonary complications (PPCs) are observed at high frequencies and are the major cause of postoperative morbidity and mortality in patients undergoing radical lung surgery.⁵–⁷ Mechanical ventilation, surgical procedure, and anesthesia can all induce a severe inflammatory response; prolonged high levels of inflammatory cytokines and neutrophil elastase are related to the development of postoperative complications.⁸

Ulinastatin, a human protease inhibitor found in urine, has the capacity to inhibit both the activity of neutrophilic elastase and the activation of proinflammatory cytokines.⁹,¹⁰ Previous studies have demonstrated that ulinastatin can improve clinical outcomes in patients with acute inflammation, such as acute pancreatitis, shock, cardiac surgery, and organ transplantation, and can alleviate acute lung injury as a result of severe burns, sepsis, esophagectomy surgery, and hemorrhagic shock.¹¹–¹⁴
Although some trials have demonstrated that ulinastatin can prevent the intraoperative and postoperative increase in proinflammatory cytokines for lung resection surgery, its impact on postoperative complications and clinical outcomes remains unknown. Therefore, we designed this randomized prospective pilot study for further multi-center research to examine the effects of intraoperative high-dose ulinastatin treatment on early postoperative clinical outcomes in patients undergoing lung resection surgery.

**Methods**

**Clinical data and grouping**

This trial was performed in accordance with the principles of the Declaration of Helsinki. The Ethical Committee of West China Hospital, Sichuan, China approved the protocol of this study. All patients signed written informed consent before entering the study.

Non-small cell lung cancer (NSCLC) stage I–IV patients (aged 30–80 years, American Society of Anesthesiologists classification ≤ III) were enrolled into the study. All patients had undergone elective radical thoracotomy in the Lung Cancer Treatment Center, West China Hospital of Sichuan University, China, in 2014 or 2015. Patients: (i) with allergies to ulinastatin; (ii) who had secondary surgery for recurrent tumors; (iii) with other malignant tumors; (iv) who required preoperative mechanical ventilation (> 1 hour) within two weeks; and (v) with a body mass index (BMI) ≥ 35 kg/m², were excluded.

The study was a randomized, prospective, placebo-controlled, double blind trial. The consecutively enrolled 108 patients were randomly assigned into ulinastatin group (group U) and control group (group C) according to the computer generated random numbers.

**Ulinastatin therapy**

Patients in group U were intravenously infused with ulinastatin (Techpool, Guangdong, China) at a rate of 20 000 U/kg/hour for the first hour after anesthesia induction and then at a rate of 5000 U/kg/hour (diluted into 20 mL using normal saline) until the conclusion of surgery. For group C, the ulinastatin solution was replaced with normal saline in the same volume and infused at the same rate. A nurse who was not participating in the study opened the randomized envelopes and prepared the study drug solution.

**Anesthetic method and perioperative management**

The same surgeon performed all surgeries. Five-lead electrocardiogram (ECG), pulse oximetry (SPO₂), end-tidal carbon dioxide tension (EtCO₂), bispectral index (BIS), invasive blood pressure (BP), and central venous pressure (CVP) were recorded throughout the surgery. Arterial blood samples were collected through the radial artery before surgery, 30 minutes after one lung ventilation (OLV), and 30 minutes after re-two lung ventilation (re-TLV). The respiratory parameters and vital signs were recorded at the same time.

Patients received volume-controlled mechanical ventilation with a tidal volume (VT) of 6–8 mL/kg of predicted body weight, a positive end-expiratory pressure (PEEP) of 6–8 cm of water and a recruitment maneuver (applying a continuous positive airway pressure of 30 cm of water for 30 seconds), repeated every 30 minutes for lung re-expansion before and after OLV to avoid atelectasis. In case of desaturation during OLV (defined as a peripheral oxygen saturation less than 90%), rescue therapy was proposed and consisted of increasing FiO₂ to 100% and continuously uptaking oxygen in the non-ventilated lung for 3–5 L/minutes or discontinuing TLV until oxygen saturation had reached the target value (oxygen saturation ≥ 90%). The fluid infusion speed was adjusted according to bleeding quantity and CVP, and blood products were used according to blood transfusion guidelines. After surgery, all patients were transferred into the intensive care unit (ICU), with a tracheal tube.

The postoperative clinical course of each patient was carefully observed daily until discharge and pulmonary complications were evaluated. For patients discharged within 30 days after surgery, information was retrieved via telephone follow-up. Postoperative complications were observed and evaluated by a blinded assessor.

Ulinastatin-related adverse events were defined as shock, rash, itching, nausea, vomiting, diarrhea, allergy, or neutropenia.

**Outcomes**

The primary outcome of the study was to determine postoperative pulmonary complications (PPCs). PPCs were defined as the presence of pneumonia, bronchopleural fistula, massive atelectasis, adult respiratory distress syndrome (ARDS), acute lung injury (ALI), or respiratory failure without signs of pneumonia and/or atelectasis that required prolonged management by artificial ventilation.

Pulmonary complications resulting from postoperative recurrent nerve palsy were excluded. PPC morbidities were attributed in a binary fashion by patient to ensure that a patient with more than one event was only counted once.

The secondary outcomes were hospital mortality, chest drainage, cardiovascular complications (arrhythmia, acute cardiac failure), wound infection, and duration of ICU and postoperative hospital stays. Operative mortality was
defined as patient death after surgery before discharge from the hospital or within 30 days of surgery.\textsuperscript{17}

Other clinical outcomes evaluated included blood routine and biochemical tests in the first 24 hours after surgery. The respiratory index (RI), dynamic lung compliance (Cdyn), and oxygenation index (OI) during surgery were calculated according to the following formulas: $RI = \frac{P(A-aO_2)}{\text{partial pressure of O}_2 \text{ in arterial blood (PaO}_2)} = \left(\frac{\text{[fraction of inspired oxygen (FiO}_2) \times (760-47]-\text{partial pressure of carbon dioxide in arterial blood (PaCO}_2)/0.8-\text{PaO}_2}}{\text{PaO}_2}\right)$; $C_{\text{dyn}} = \frac{(C_{\text{dyn}} \text{[mL/cmH}_2\text{O]})}{\text{VT/(Pmax-PEEP)}}$; and $OI = \frac{\text{PaO}_2}{\text{FiO}_2}$.

**Statistical analysis**

Statistical analyses were carried out with SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Normally distributed continuous data were expressed as mean ± standard deviation; non-normal distributed data were expressed as median (interquartile range). Enumeration data were expressed as count proportion. One-way analysis of variance was used for continuous variables. Chi-square or Fisher’s exact tests were used to compare categorical data. $P$ values < 0.05 were considered statistically significant.

**Results**

**Baseline characteristics of enrolled patients**

Between November 2014 and August 2015, of 338 patients screened, 117 patients were enrolled; 108 (92.31%) patients completed the pilot study, with 52 in the ulinastatin and 56 in the control group (Fig 1).

The baseline patient characteristics were balanced between the two groups ($P > 0.05$), except for base excess (BE), which was lower in group U ($-0.28 \pm 1.67$) than in group C ($0.49 \pm 1.91$; $P = 0.046$; Table 1).

**Clinical outcomes**

**Primary clinical outcome**

Primary clinical outcomes are presented in Table 2. Similar results were obtained between the two groups for primary clinical outcomes. PPCs were observed in 20 patients (38.46%) in group U and 27 (48.21%) in group C. Pulmonary complications occurred less frequently in group U; however, there was no significant difference ($P = 0.307$).

**Secondary clinical outcomes**

Secondary clinical outcomes are presented in Table 2. Except for chest drainage duration, no significant differences were observed between the groups ($P > 0.05$). Chest drainage duration in eight patients (15.4%) in group U and 18 (32.1%) in group C was longer than five days ($P = 0.039$). Hospital mortality did not differ between the groups ($P = 0.649$). Two patients in each group died within 30 days after surgery. There were no differences in the amount of chest drainage, arrhythmia, heart failure, or length of ICU or postoperative hospital stay between the two groups ($P > 0.05$).

The level of postoperative creatinine in the serum in group U (87.31 ± 33.16) was higher than in group C (80.53 ± 19.95; $P = 0.013$; Table 3). Other postoperative clinical courses between the two groups were similar ($P > 0.05$).

**Intraoperative respiratory index**

There were no significant differences observed in RI, OI, or Cdyn at all three time points (preoperative; OLV 30 minutes; re-TLV 30 minutes) between the two groups ($P > 0.05$; Fig 2).

**Safety analysis**

No adverse events related to ulinastatin administration were observed during the study.
**Discussion**

In this clinical trial, the observed rate of postoperative complications was slightly higher than previously reported (3.3–40%). Of the 108 patients enrolled, 38.46% patients in the U group and 48.21% in the control developed pulmonary complications. In part, this was a result of the inclusion of NSCLC stage III–IV patients (61.11%) who experienced more extensive surgery trauma, as well as patients with chronic obstructive pulmonary disease (varying from mild to severe), both of which are associated with increased morbidity rates. Most previously reported studies only included early stage NSCLC patients with almost normal lung function.

Continuous intraoperative infusion of high-dose ulinastatin was not observed to lead to significantly improved clinical outcomes after radical lung cancer resection in this

| Table 1 Baseline patient characteristics | Ulinastatin (n = 52) | Control (n = 56) | P |
|-----------------------------------------|---------------------|-----------------|---|
| **Characteristic**                      |                     |                 |   |
| Age (years)                             | 61 (53.00–66.00)    | 60.0 (51.25–60.00) | 0.319 |
| Gender (male/female)                    | 37/15               | 41/15           | 0.832 |
| Height (cm)                             | 165.12 ± 6.153      | 164.38 ± 6.57   | 0.556 |
| Weight (kg)                             | 62.0 ± 9.16         | 61.40 ± 9.11    | 0.735 |
| Body-mass index (kg/m²)                 | 22.82 ± 2.81        | 22.67 ± 2.56    | 0.756 |
| **Lung function**                       |                     |                 |   |
| FEV1/FVC (%)                            | 73.79 ± 10.21       | 71.06 ± 13.37   | 0.265 |
| FVC (L)                                 | 3.05 ± 0.8          | 3.13 ± 0.82     | 0.643 |
| FEV1/FVC (%)                            | 73.79 ± 9.76        | 71.06 ± 13.37   | 0.265 |
| **Chemical test**                       |                     |                 |   |
| PaO2                                     | 80.57 ± 9.63        | 79.57 ± 19.67   | 0.764 |
| PaCO2                                    | 36.49 ± 2.90        | 38.69 ± 7.25    | 0.065 |
| BE                                       | -0.28 ± 1.67        | 0.49 ± 1.91     | 0.046* |
| **Pre-existing comorbid condition**     |                     |                 |   |
| Hypertension                             | 6                   | 6                | 0.553 |
| Diabetes mellitus                       | 11                  | 13               | 0.567 |
| Heart disease                            | 29                  | 27               | 0.542 |
| COPD                                     | 6                   | 4                | 0.412 |
| Type of surgery                          | 4                   | 4                | 0.993 |
| Sublobectomy                             | 4                   | 5 (8.93%)        | 0.993 |
| Lobectomy                                | 33 (63.46%)         | 36 (64.29%)     | 0.627 |
| Biectomy                                 | 13 (25.00%)         | 13 (23.21%)     | 0.542 |
| Pneumonectomy                            | 2 (3.8%)            | 2 (3.4%)        | 0.542 |
| Blood loss during surgery (mL)           | 10.21 ± 35.18       | 18.37 ± 35.18   | 0.046* |
| Blood loss during surgery (minutes)      | 10.21 ± 35.18       | 18.37 ± 35.18   | 0.046* |
| Duration of OLV (minutes)                | 14.97 ± 57.22       | 147.11 ± 58.41  | 0.508 |

*P < 0.05 compared with the control. ABG, arterial blood gases; ASA, American Society of Anesthesiologists; BE, base excess; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; OLV, one lung ventilation; PaO2, partial pressure of O2 in arterial blood; PaCO2, partial pressure of carbon dioxide in arterial blood.

**Table 2** Effect of ulinastatin on postoperative clinical outcomes

| Outcome                               | Ulinastatin (n = 52) | Control (n = 56) | P   |
|---------------------------------------|----------------------|-----------------|-----|
| **Primary outcome**                   |                      |                 |     |
| Pneumonia (n)                         | 14 (26.92%)          | 16 (28.57%)     | 0.808 |
| Bronchopleural (n)                    | 3 (5.8%)             | 2 (3.6%)        | 0.465 |
| Fistula (n)                            |                      |                 |     |
| Respiratory failure (n)               | 8 (15.38%)           | 7 (12.50%)      | 0.665 |
| ARDS/ALI (n)                          | 11 (21.15%)          | 14 (25.00%)     | 0.636 |
| Total                                 | 20 (38.46%)          | 27 (48.21%)     | 0.307 |
| **Secondary outcomes**                |                      |                 |     |
| Hospital mortality (n)                | 2 (3.8%)             | 2 (3.4%)        | 0.649 |
| Chest drainage ≥ 5 days (n)           | 8 (15.4%)            | 18 (32.1%)      | 0.039* |
| Chest drainage (mL)                   | 761.30 ± 541.49      | 836.45 ± 582.79 | 0.514 |
| Arhythmia (n)                         | 7 (13.5%)            | 15 (26.8%)      | 0.069 |
| Heart failure (n)                     | 1 (1.9%)             | 1 (1.8%)        | 0.733 |
| Wound infection (n)                   | 2 (3.8%)             | 3 (5.63%)       | 0.709 |
| Length of stay, median (IQR)          |                     |                 |     |
| ICU (days)                            | 3.49 ± 1.82          | 3.78 ± 2.34     | 0.492 |
| Postoperative hospital (days)         | 12.71 ± 3.33         | 13.16 ± 4.09    | 0.574 |

*P < 0.05 compared to control. ARDS, adult respiratory distress syndrome; ALI, acute lung injury; ICU, intensive care unit; IQR, interquartile range.

**Table 3** Effect of ulinastatin on postoperative laboratory values

| Laboratory value                       | Ulinastatin (n = 52) | Control (n = 56) | P   |
|---------------------------------------|----------------------|-----------------|-----|
| **Routine blood count (pod1)**        |                      |                 |     |
| WBC count                             | 14.81 ± 3.71         | 15.18 ± 3.89    | 0.627 |
| Neutrophil (%)                        | 87.04 ± 5.09         | 87.53 ± 3.40    | 0.566 |
| Lymphocyte (%)                        | 6.33 ± 3.85          | 6.20 ± 2.20     | 0.853 |
| **Biochemical test**                  |                      |                 |     |
| BUN                                    | 6.43 ± 2.03          | 6.5519 ± 1.76   | 0.748 |
| Cr                                      | 87.31 ± 33.16        | 80.81 ± 19.95   | 0.013* |
| LDH                                    | 226.80 ± 41.25       | 237.59 ± 58.63  | 0.135 |

*P < 0.05 compared to control. BUN, blood urea nitrogen; Cr, creatinine; LDH, lactate dehydrogenase; WBC, white blood cell.
trial. Ulinastatin has been shown in previous studies to alleviate inflammatory response and to improve the respiratory parameters in patients undergoing lung resection surgery.\textsuperscript{22,23} Few studies, especially prospective, randomized, and controlled studies, however, have observed the effect of ulinastatin on clinical outcomes in patients undergoing radical lung cancer resection. Although some studies found that ulinastatin was effective in the treatment of ALI and ARDS, these findings were mainly from patients with sepsis, acute pancreatitis, and burn injuries, and the treatment always lasted for a long period.\textsuperscript{24–26} A systematic meta-analysis demonstrated that ulinastatin significantly decreased ICU mortality and the length of ICU stay in patients with ALI and ARDS, while 28-day mortality was not significantly affected.\textsuperscript{27} Another systematic meta-analysis revealed that intraoperative ulinastatin did not affect hospital mortality, postoperative complication rate, or length of ICU stay in patients undergoing cardiac surgery.\textsuperscript{13} Lung cancer surgery consists of complex trauma, including the surgical removal of part of lung, OLV, mechanical ventilation, and anesthesia, which can induce pulmonary and systemic injuries. In our study, over 60\% of the patients were stage III–IV NSCLC patients, considered high-risk. Our results suggest that ulinastatin may have limited benefits for high-risk patients or those undergoing complicated surgery. However, injuries caused by lung surgery may last days or weeks, and ulinastatin was only used during surgery in our study. Further research is required to determine whether prolonged administration of ulinastatin after surgery is of benefit.

Pulmonary complications occurred less frequently in patients treated with ulinastatin (38.46\% in group U vs. 48.21\% in group C). We also observed that ulinastatin administration led to a shorter duration of postoperative chest drainage. These findings suggest, to some extent, that intraoperative ulinastatin might promote the recovery of lung injuries caused by surgery.\textsuperscript{25} As a protease inhibitor of neutrophil elastase, ulinastatin can alleviate pulmonary edema, hemorrhage, and inflammatory exudation in acute lung injuries through mitigation of the inflammatory reaction and inhibition of immunosuppression.\textsuperscript{28–31}

We used ulinastatin at high doses until the conclusion of surgery. It has been demonstrated that ulinastatin works in a dose-dependent manner and was safe at a dose of 20 000 U/kg in a tolerance trial.\textsuperscript{26,32–34} Thus, we designed this pilot study to treat patients with ulinastatin at 20 000 U/kg/hour for the first hour after anesthesia induction and then 5000 U/kg/hour until the conclusion of surgery in an attempt to achieve the maximal anti-inflammatory effect. This practice suggested that an increase in the dose of ulinastatin during surgery might be limited; however, an examination of the use of ulinastatin after surgery may be worth further trials.

Our study has some limitations. As only 108 patients were enrolled, the population might not be large enough to determine differences. Large-scale research is needed for verification of the possible protective effects of ulinastatin in thoracotomy patients. The patients enrolled underwent four types of surgeries: sublobectomy, lobectomy, biolocectomy, and peneumonectomy. Although the distribution between U and C groups was well balanced, this might be a confounding factor and requires further stratified analysis. We only measured direct clinical indicators and did not measure inflammatory markers in this pilot study. As mentioned, ulinastatin reduces the injury caused by inflammatory response; therefore, the protective effect of ulinastatin may be reflected by changes in inflammatory markers. Finally, we did not observe the effect of ulinastatin on long-term outcomes. Ulinastatin is believed to not only protect tissues and organs from severe inflammatory response, but also inhibit tumor invasion and metastasis.\textsuperscript{9,35}

Further studies are necessary to confirm the inhibitory effect of ulinastatin on lung cancer invasion and metastasis.

In summary, the present study revealed no significant positive effects of ulinastatin on postoperative pulmonary

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure2}
\caption{Changes to intraoperative respiratory parameters. (a) Respiratory index; (b) oxygenation index; (c) dynamic lung compliance (Cdyn). T1, preoperative; T2, one lung ventilation 30 minutes; T3, re-two lung ventilation 30 minutes.}
\end{figure}
complications and other outcomes for lung cancer patients undergoing radical thoracotomy. However, a protective trend of ulinastatin was observed. Further research is warranted.

**Acknowledgments**

This study was supported by the Natural Science Foundation of China (NSFC; 30571785; 30972862); the Sichuan Projects of China (2012FZ0121); and the Techpool Research Fund.

**Disclosure**

No authors report any conflict of interest.

**References**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29.
2. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: Epidemiology, etiology, and prevention. Clin Chest Med 2011; 32: 605–44.
3. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
4. Zhou Q, Liu B, Yang J et al. Carinal resection and reconstruction combined with heart and great vessel plasty in the treatment of locally advanced non-small cell lung cancer.] Zhongguo Fei Ai Za Zhi 2006; 9: 2–8. (In Chinese.)
5. Agostini P, Cieslik H, Rathinam S et al. Postoperative pulmonary complications following thoracic surgery: Are there any modifiable risk factors? Thorax 2010; 65: 815–8.
6. Thomas PA, Berbis J, Baste JM et al. Pneumonectomy for lung cancer: Contemporary national early morbidity and mortality outcomes. J Thorac Cardiovasc Surg 2015; 149: 73–82.
7. Jin Y, Xie G, Wang H et al. Incidence and risk factors of postoperative pulmonary complications in noncardiac Chinese patients: A multicenter observational study in university hospitals. Biomed Res Int 2015; 2015: 265165.
8. Loher S, Slinger P. Lung injury after one-lung ventilation: A review of the pathophysiological mechanisms affecting the ventilated and the collapsed lung. Anesth Analg 2015; 121: 302–18.
9. Shigetomi H, Onogi A, Kajiwara H et al. Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain. Inflamm Res 2010; 59: 679–87.
10. Inoue K, Takano H. Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders. Expert Opin Investig Drugs 2010; 19: 513–20.
11. Seta T, Noguchi Y. Protease inhibitors for preventing complications associated with ERCP: An updated meta-analysis. Gastrointest Endosc 2011; 73: 700–706.e1–2.
12. Yuhara H, Ogawa M, Kawaguchi Y, Igashira M, Shimosegawa T, Mine T. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: Protease inhibitors and NSAIDs in a meta-analysis. J Gastroenterol 2014; 49: 388–99.
13. He QL, Zhong F, Ye J et al. Does intraoperative ulinastatin improve postoperative clinical outcomes in patients undergoing cardiac surgery: A meta-analysis of randomized controlled trials. Biomed Res Int 2014; 2014: 630835.
14. Abu-Amara M, Gurusamy K, Hori S, Glantzounis G, Fuller B, Davidson BR. Systematic review of randomized controlled trials of pharmacological interventions to reduce ischaemia-reperfusion injury in elective liver resection with vascular occlusion. HPB (Oxford) 2010; 12: 4–14.
15. Futier E, Constantijn JM, Paugam-Burtz C et al. A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. N Engl J Med 2013; 369: 428–37.
16. Arslantas MK, Kara HV, Tuncer BB et al. Effect of the amount of intraoperative fluid administration on postoperative pulmonary complications following anatomic lung resections. J Thorac Cardiovasc Surg 2015; 149: 314–20, 21.e1.
17. Freeman RK, Dils JR, Ascioti AJ, Dake M, Mahidhara RS. A comparison of length of stay, readmission rate, and facility reimbursement after lobectomy of the lung. Ann Thorac Surg 2013; 96: 1740–5.
18. Schussler O, Alifano M, Dermise H et al. Postoperative pneumonia after major lung resection. Am J Respir Crit Care Med 2006; 173: 1161–9.
19. Gao K, Yu PM, Su JH et al. Cardiopulmonary exercise testing screening and pre-operative pulmonary rehabilitation reduce postoperative complications and improve fast-track recovery after lung cancer surgery: A study for 342 cases. Thorac Cancer 2015; 6: 443–9.
20. Putila J, Guo NL. Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer. PLoS One 2014; 9 (6): e100994.
21. Ghaly G, Kamel M, Nasar A et al. Video-assisted thoracoscopic surgery is a safe and effective alternative to thoracotomy for anatomical segmentectomy in patients with clinical stage I non-small cell lung cancer. Ann Thorac Surg 2016; 101: 465–72.
22. Liu XZ, Wang ZG, Wei CW et al. [Protective effects of ulinastatin on pulmonary tissue of patients with unilateral ventilation during operation.] Med J Chin PLA 2009; 34: 894–5. (In Chinese.)
23. He Y, Wu QJ, Man F, Liu B. [Effect of ulinastatin on oxygen free radical and inflammatory factors during one lung ventilation, a systematic review.] Sichuan Med J 2012; 33: 2068–70. (In Chinese.)
24 Xu CE, Zou CW, Zhang MY, Guo L. Effects of high-dose ulinastatin on inflammatory response and pulmonary function in patients with type-A aortic dissection after cardiopulmonary bypass under deep hypothermic circulatory arrest. *J Cardiothorac Vasc Anesth* 2013; 27: 479–84.

25 Sato A, Kuwabara Y, Shinoda N, Kimura M, Ishiguro H, Fujii Y. Use of low dose dopamine, gabexate mesilate and ulinastatin reduces the water balance and pulmonary complication in thoracic esophagectomy patients. *Dis Esophagus* 2005; 18: 151–4.

26 Bao P, Zhao W, Li Y, Liu Y, Zhou Y, Liu C. Protective effect of ulinastatin in patients with non-small cell lung cancer after radiation therapy: A randomized, placebo-controlled study. *Med Oncol* 2015; 32: 405.

27 Leng YX, Yang SG, Song YH, Zhu X, Yao GQ. Ulinastatin for acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis. *World J Crit Care Med* 2014; 3: 34–41.

28 Zhou G, Xu Q, Liu Y, Wang Z, Su L, Guo X. [Protective effects of ulinastatin against acute lung injury induced by heatstroke in mice.] *Nan Fang Yi Ke Da Xue Xue Bao* 2015; 35: 1277–82. (In Chinese.)

29 Zhang Y, Qiu X, Zhou G, Liu Z, Chang N, Jia C. [Early effects of ulinastatin by aerosol inhalation on rabbits with lipopolysaccharide-induced acute lung injury.] *Zhonghua Shao Shang Za Zhi* 2014; 30: 203–7. (In Chinese.)

30 Qin ZS, Tian P, Wu X, Yu HM, Guo N. Effects of ulinastatin administered at different time points on the pathological morphologies of the lung tissues of rats with hyperthermia. *Exp Ther Med* 2014; 7: 1625–30.

31 Ma WH, Wu YL, Li ZX et al. [Protective effects of ulinastatin on lung in patient undergoing lung resection after chemotherapy.] *Chin J Anesthesiol* 2006; 26: 39–42. (In Chinese.)

32 Binns OA, DeLima NF, Buchanan SA et al. Neutrophil endopeptidase inhibitor improves pulmonary function during reperfusion after eighteen-hour preservation. *J Thorac Cardiovasc Surg* 1996; 112: 607–13.

33 Luo GJ, Yao WF, He Y, Luo CF, Li XY, Hei ZQ. Ulinastatin prevents acute lung injury led by liver transplantation. *J Surg Res* 2015; 193: 841–8.

34 Wu CY, Xiao F, Gen L, Xu Q, Yu XQ. [Tolerance of ulinastatin in healthy volunteers.] *Chin J Clin Pharmacol* 2007; 12: 103–6. (In Chinese.)

35 Fries E, Blom AM. Bikunin—not just a plasma proteinase inhibitor. *Int J Biochem Cell Biol* 2000; 32: 125–37.